US Gene Editing Market

ID: MRFR/LS/11815-HCR

100 Pages

Garvit Vyas

September 2025

US Gene Editing Market Research Report: By Technology (CRISPR, TALEN, ZFN, Antisense, others), By Application (Genetic Engineering, Gene Therapy, Cell Line Engineering, Others), By Method (Ex-vivo, In-vivo) and By End User (Biotechnology and Pharmaceutical Companies, Contract Research Organizations (CROs), Academic & Government Research Institutes) - Forecast to 2035

Single User

$ 4,950.0

Multiple License

$ 5,950.0

Enterprise User

$ 7,250.0

Summary Table of Contents Segmentation Infographic

1. Market Overview

2. Market Trends

3. Market Segment Insights

4. Key Players and Competitive Insights

5. Industry Developments

6. Market Segmentation

7. Report Scope

8. Market Highlights

9. FAQs

Customize Report

Certified Researchers

US Gene Editing Market Summary

The United States gene editing market is poised for substantial growth, projected to reach 18 USD billion by 2035.

Key Market Trends & Highlights

US Gene Editing Key Trends and Highlights

The market valuation is estimated at 2.5 USD billion in 2024, indicating a robust starting point for growth.
From 2025 to 2035, the market is expected to grow at a compound annual growth rate of 19.66 percent.
By 2035, the gene editing market in the United States is anticipated to expand to 18 USD billion, reflecting increasing demand.
Growing adoption of gene editing technologies due to advancements in research and development is a major market driver.

US Gene Editing Market

CAGR

19.66%

Market Size & Forecast

2024 Market Size	2.5 (USD Billion)
2035 Market Size	18 (USD Billion)
CAGR (2025-2035)	19.66%

Major Players

Editas Medicine, Cellectis, Amgen, Novartis, Bluebird Bio, Sangamo Therapeutics, Thermo Fisher Scientific, Inovio Pharmaceuticals, Illumina, CRISPR Therapeutics, Intellia Therapeutics, Precision BioSciences, Applied StemCell, Regeneron Pharmaceuticals, Vertex Pharmaceuticals

US Gene Editing Market Trends

The US Gene Editing Market is witnessing significant advancements driven by several key market drivers. One major driver is the increasing investment in research and development from both government and private sectors, aimed at harnessing gene editing technologies for therapeutic applications.

The National Institutes of Health and the Department of Agriculture in the US have been supporting various gene editing projects, focusing on areas like agriculture and healthcare.

Additionally, the rising prevalence of genetic disorders and the demand for personalized medicine are fueling the growth of gene editing applications. Opportunities to be explored in the US include the development of CRISPR-associated therapies that can provide efficient solutions for conditions such as sickle cell disease and certain cancers.

The agricultural sector also presents substantial market opportunities, particularly in crop enhancement and food security, aligning with the US government's interests in sustainable agricultural practices.

Moreover, with increased collaboration between biotech firms and academic institutions, various innovative applications of gene editing are emerging that can advance areas such as regenerative medicine. Trends in recent times indicate a push for regulatory clarity surrounding gene editing techniques, as organizations like the FDA and USDA work to outline guidelines for the safe use of these technologies.

Public engagement and education regarding gene editing's benefits and ethical considerations are becoming increasingly relevant, as discussions about gene safety and biodiversity gain attention in the US.

Additionally, the ongoing development of more precise, effective, and ethical gene editing methods continues to shape the market landscape, allowing for broader acceptance within both scientific and public communities.

Overall, the US Gene Editing Market is positioned for growth, with a focus on addressing health challenges and agricultural needs through innovative gene editing solutions.

Market Segment Insights

Gene Editing Market Technology Insights

The US Gene Editing Market has seen substantial advancements in the Technology segment, particularly with the emergence of various methodologies that are pivotal in driving innovation and research. Within this landscape, CRISPR technology stands out for its simplicity and efficiency, enabling precise gene modification with minimal off-target effects.

Its widespread application in biotechnology, agriculture, and healthcare has made it a cornerstone of gene editing efforts in the US.

Meanwhile, TALEN (Transcription Activator-Like Effector Nucleases) technology offers the advantage of creating custom nucleases for specific DNA sequences, thereby facilitating targeted gene edits with robust applications in therapeutics and crop enhancement.

ZFN (Zinc Finger Nucleases) serves as another critical technology, allowing for the targeting of specific DNA sequences for alterations, commonly used in gene therapy and genetic engineering. Although it is more complex compared to CRISPR, its capabilities in generating knockout models have positioned it as a valuable tool in biological research.

Antisense technology, which employs short nucleic acid sequences to bind to mRNA, is extensively utilized in developing therapies that can silence specific genes, thus showing potential in treating various genetic disorders and cancers. The continued growth in the field of synthetic biology and increased funding in innovative biotechnologies support the expansion of these technologies.

Gene Editing Market Application Insights

The Application segment of the US Gene Editing Market encompasses various critical areas such as Genetic Engineering, Gene Therapy, Cell Line Engineering, and others, each playing a pivotal role within the industry.

Genetic Engineering has transformed agricultural practices by enhancing crop quality and resistance to environmental stresses, addressing food security challenges in the United States.

Meanwhile, Gene Therapy continues to gain traction as a promising method for treating genetic disorders, significantly influencing patient care and outcomes.

Cell Line Engineering is crucial for pharmaceutical development, providing a platform for producing more effective therapies and vaccines. As the US government accelerates Research and Development initiatives in biotechnology, opportunities for these applications are expanding, bolstered by rising investments and advances in technology.

The growing demand for personalized medicine and effective treatments further drives the evolution of the US Gene Editing Market. However, regulatory challenges and ethical considerations still pose hurdles to the widespread adoption of these applications.

Gene Editing Market Method Insights

The US Gene Editing Market focused on method segmentation is witnessing robust growth, driven by the increasing applications of gene editing technologies across various fields such as healthcare, agriculture, and biotech.

The methods utilized in this market include Ex-vivo and In-vivo techniques. Ex-vivo methods are critical as they allow for the modification of cells outside the patient's body before being reintroduced, offering significant advantages in treating genetic disorders and ensuring safety.

This approach facilitates precise targeting and high levels of customization tailored to individual patient needs. In contrast, In-vivo methods involve the direct introduction of gene editing tools into the patient's body, making them essential for real-time applications in gene therapy and regenerative medicine.

These techniques are gaining traction due to technological advancements and the growing prevalence of chronic diseases that demand innovative treatment solutions.

The ongoing research is addressing challenges in both delivery mechanisms and efficiency, unlocking new opportunities for stakeholders within the US Gene Editing Market industry. Consequently, the method segmentation showcases a promising landscape ripe for innovations, enhanced capabilities, and impactful applications that contribute to the healthcare and biotechnology sectors.

Gene Editing Market End User Insights

The End User segment of the US Gene Editing Market is characterized by a diverse array of participants, primarily including Biotechnology and Pharmaceutical Companies, Contract Research Organizations, and Academic and Government Research Institutes.

These entities play significant roles in advancing gene editing technologies and their applications across various therapeutic areas.

Biotechnology and Pharmaceutical Companies are critical as they spearhead innovative therapies that leverage gene editing to address genetic disorders and other diseases, thus driving substantial market growth.

Contract Research Organizations provide essential services that accelerate the research and development process, allowing for efficient study designs and regulatory compliance.

Meanwhile, Academic and Government Research Institutes contribute foundational knowledge and breakthroughs, often collaborating with industry players to develop cut-ting-edge applications.

Get more detailed insights about US Gene Editing Market

Request Free Sample

Key Players and Competitive Insights

The US Gene Editing Market is characterized by rapid advancements and intense competition among biotechnology firms that are pioneering innovative technologies for gene manipulation. This market has garnered significant attention due to its potential applications in treating genetic diseases, advancing agricultural practices, and enhancing biopharmaceutical developments.

The competitive landscape is shaped by a mix of established companies and emerging startups, each vying for technological superiority and market share. The ongoing research and development activities coupled with strategic collaborations, partnerships, and investments have intensified the competition, leading to a dynamic environment where companies are continuously seeking to outperform their rivals through novel solutions and products.

Editas Medicine

Editas Medicine has carved out a significant position within the US Gene Editing Market through its focus on CRISPR technology. The company has developed a strong portfolio of gene editing therapies aimed at treating genetic disorders, particularly in the realms of ophthalmology and hematology. Editas Medicine's strengths lie in its proprietary technologies and robust intellectual property position, which provide a competitive edge in the development of transformative therapies.

The company has also established numerous partnerships with academic institutions and pharmaceutical firms, facilitating access to additional resources and expertise that enhance its research capabilities. Its commitment to advancing its pipeline of therapies combined with a clear regulatory strategy allows it to maintain an influential role in the evolving gene editing landscape.

Cellectis

Cellectis operates in the US Gene Editing Market with a strong emphasis on gene editing solutions that harness the power of its TALEN technology. Cellectis has developed several key products that cater to the biopharmaceutical sector, particularly in the development of CAR T-cell therapies for oncology, showcasing its expertise in transforming patient treatment options.

The company's strategic focus on building robust collaborations, particularly within the gene and cell therapy sectors, has bolstered its market presence. Cellectis has pursued mergers and acquisitions to enhance its capabilities and expand its technology platform, exemplifying its ambition to be a leader in the competitive gene editing arena.

With a solid pipeline and a keen focus on innovative therapeutic approaches, Cellectis is positioned to leverage its advancements to capture significant market share in the US gene editing sector.

Key Companies in the US Gene Editing Market market include

Industry Developments

The US Gene Editing Market has witnessed significant developments, including increased research in CRISPR technology and advancements in personalized medicine. Companies such as Editas Medicine and CRISPR Therapeutics are leading efforts to leverage gene editing for therapeutic applications, particularly in genetic disorders and cancer treatment.

Notably, in July 2023, Amgen acquired a small biotech firm, enhancing their gene editing capabilities and expanding their portfolio in precision medicine.

Regulatory backing is also notable; in September 2023, the FDA approved novel gene therapies, reflecting growing confidence in gene editing as a viable treatment option. Furthermore, Illumina's partnership with the Broad Institute has catalyzed innovation in genomic sequencing, supporting the development of gene editing applications.

The market's growth is propelled by increasing funding from government initiatives, with the National Institutes of Health allocating substantial grants for gene editing research.

Over the past two years, companies like Vertex Pharmaceuticals and Bluebird Bio have reported successful clinical trials that promise to revolutionize treatment paradigms, ensuring that the US remains at the forefront of gene editing advancements. As of October 2023, the US gene editing market continues to expand, driven by technological innovations and strategic collaborations among key players.

Market Segmentation

Gene Editing Market Method Outlook

Ex-vivo
In-vivo

Gene Editing Market End User Outlook

Biotechnology and Pharmaceutical Companies
Contract Research Organizations (CROs)
Academic & Government Research Institutes

Gene Editing Market Technology Outlook

CRISPR
TALEN
ZFN
Antisense
others

Gene Editing Market Application Outlook

Genetic Engineering
Gene Therapy
Cell Line Engineering
Others

Report Scope

Report Scope:

Report Attribute/Metric Source:	Details
MARKET SIZE 2018	1.73(USD Billion)
MARKET SIZE 2024	2.5(USD Billion)
MARKET SIZE 2035	18.0(USD Billion)
COMPOUND ANNUAL GROWTH RATE (CAGR)	19.657% (2025 - 2035)
REPORT COVERAGE	Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR	2024
MARKET FORECAST PERIOD	2025 - 2035
HISTORICAL DATA	2019 - 2024
MARKET FORECAST UNITS	USD Billion
KEY COMPANIES PROFILED	Editas Medicine, Cellectis, Amgen, Novartis, Bluebird Bio, Sangamo Therapeutics, Thermo Fisher Scientific, Inovio Pharmaceuticals, Illumina, CRISPR Therapeutics, Intellia Therapeutics, Precision BioSciences, Applied StemCell, Regeneron Pharmaceuticals, Vertex Pharmaceuticals
SEGMENTS COVERED	Technology, Application, Method, End User
KEY MARKET OPPORTUNITIES	CRISPR technology advancements, Agricultural biotechnology applications, Therapeutics for genetic disorders, Personalized medicine developments, Growth in regenerative medicine solutions
KEY MARKET DYNAMICS	Regulatory advancements, Increasing R&D investments, Growing healthcare applications, Rising public acceptance, Competitive landscape evolution
COUNTRIES COVERED	US

FAQs

What is the expected market size of the US Gene Editing Market in 2024?

The US Gene Editing Market is expected to be valued at 2.5 USD Billion in 2024.

How large is the US Gene Editing Market projected to be by 2035?

By 2035, the US Gene Editing Market is projected to grow significantly to 18.0 USD Billion.

What is the expected compound annual growth rate (CAGR) for the US Gene Editing Market from 2025 to 2035?

The US Gene Editing Market is expected to witness a CAGR of 19.657 percent from 2025 to 2035.

Which technology segment holds the largest market share in the US Gene Editing Market in 2024?

In 2024, the CRISPR segment holds the largest market share, valued at 1.0 USD Billion.

What is the projected market size for the TALEN technology segment by 2035?

The TALEN technology segment is projected to reach 3.5 USD Billion by 2035.

Who are the key players in the US Gene Editing Market?

Key players include Editas Medicine, Cellectis, Amgen, Novartis, and Bluebird Bio among others.

What is the expected market size for the ZFN technology segment in 2024?

The ZFN technology segment is expected to be valued at 0.4 USD Billion in 2024.

What are the growth drivers for the US Gene Editing Market?

Key growth drivers include advancements in gene editing technologies and increasing applications in therapeutics.

How is the Antisense technology segment expected to perform by 2035?

The Antisense segment is anticipated to grow to 1.7 USD Billion by 2035.

What challenges does the US Gene Editing Market face currently?

The market faces challenges such as regulatory hurdles and ethical concerns surrounding gene editing applications.

Free Sample Request

Kindly complete the form below to receive a free sample of this Report

Customer Stories

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Victoria Milne Founder

Case Study

Chemicals and Materials

Global Magnesium Sulfate Market – Forecast till 2027